A raster-vector approach to GIS modelling: Natural Quality cartography

The Surveying Department and the Transport Research Centre of the Polytechnic University ofMadrid (TRANSyT) cooperated on a research project where the generation of a Natural Quality map for the Peninsular Spain and Balearic Islands was one of the main outcomes. The main purpose of this cartography is to assist on the development of Environmental Reports for Strategic Environmental Assessments procedures. Some local, regional, national and international organizations have been consulted in order to obtain suitable GIS thematic databases, including the recent Spanish infrastructure of spatial data (IDEE), the European Environmental Agency and the Spanish nature data bank. The methodology begins with integration and normalization processes of data format (ESRI coverage), data accuracy (100 m), projection and datum (Lambert Azimuthal Equal Area – European Terrestrial Reference System 1989) with the aim of homogenising spatial data sets. The generation of this Natural Quality map implies the combination of a significant number of maps, finally 12. This high number of variables resulted in a very complex methodology, which forced researchers to work with raster data instead of vector. Raster combination of data has proved to be an efficient way of simulating a vector approach for a high number of datasets. This resulted in a raster map which attribute data was a vector comprising information from 12 environmental variables. Finally, a synthetic map was yielded through reclassification of the vector previously obtained. This map was assessed for consistency using various protected areas. The developed methodology, based on the used of GIS, has demonstrated the viability of implementation and convenience for future analysis

Effects of early or late-evening fatiguing physical activity on sleep quality in non-professional sportsmen

[Abstract] Background: This study aims to understand whether night sleep-quality is distorted by fatiguing physical activity (PA) when conducted early or late in the evening. Methods: Nine males (18-38yrs) performed sessions of fatiguing-PA over 3 consecutive days (Mon-Wed), for 2 weeks. One week the PA was performed at 17h, and in the other week at 21h. A Control-week included no PA (PAABSENT). The fatiguing-PA sessions comprised several sets of the 20m Shuttle-Run-Test (20mSRT). Sleep was assessed by actigraphic recordings acquired over three nights each week. It included the nights following the PA-sessions and the same days in the week of PAABSENT. Sleep-quality perception was evaluated by mean of the National Sleep Foundation-Sleep Diary. The heart-rate (HR) and body-temperature (BT) at bed-time and waking-up were also registered. Results: Neither the 20mSTR-estimated VO2max nor the number of maximal 20mSRT sets were different in the PA17h and PA21h sessions. Compared to the PAABSENT, the PA17h and PA21h sessions increased the HR at bedtime, which recovered to baseline level after the night of sleep. BT was also reduced when waking-up compared to bed-time, but this was also observed in PAABSENT. Sleep parameters measured by means of actigraphy were not modified by fatiguing activity when compared to PAABSENT. Nevertheless, the subjective perception of sleep-quality was negatively altered by fatiguing PA. Conclusions: Fatiguing PA performed early or late at the evening has no impact on objective sleep-quality but, subjectively, a deterioration of sleep-quality is perceived by the subjects

Ensayo metodológico de planificación física de una autovía en el Estado Miranda (Venezuela)

La planificación física con base ecológica es fundamental para desarrollar el potencial ambiental y humano de un territorio. Sin embargo, en numerosas áreas de Latinoamérica hay carencias de información territorial que dificultan estos procedimientos. En esta línea, se ha realizado un ensayo metodológico de una planificación física de una autovía hipotética. Para ello se han realizado modelos en SIG (Sistemas de Información Geográfica) de capacidad territorial, riesgos, calidad, fragilidad e impacto ambiental, que se han integrado en una síntesis de planificación territorial. El objetivo final ha sido modelizar un mapa de impedancia o fricción frente a la autovía, para aplicar un algoritmo cost distance / cost path y obtener un trazado de autovía que optimizase la capacidad del territorio y minimizase el impacto ambiental. Se ha consolidado un aprendizaje y una primera transferencia I + D dirigida a la gestión territorial y a la toma de decisiones para diversos países de Latinoamérica

Atrial Fibrillation Originating in the Inferior Vena Cava

Recurrence of atrial fibrillation (AF) despite successful isolation of the pulmonary veins (PVs) represents a great challenge. We present a patient with recurrent episodes of paroxysmal AF despite PV isolation in which a non-PV trigger was identified in the inferior vena cava. (Level of Difficulty: Intermediate.

Clonal chromosomal mosaicism and loss of chromosome Y in elderly men increase vulnerability for SARS-CoV-2

The pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID-19) had an estimated overall case fatality ratio of 1.38% (pre-vaccination), being 53% higher in males and increasing exponentially with age. Among 9578 individuals diagnosed with COVID-19 in the SCOURGE study, we found 133 cases (1.42%) with detectable clonal mosaicism for chromosome alterations (mCA) and 226 males (5.08%) with acquired loss of chromosome Y (LOY). Individuals with clonal mosaic events (mCA and/or LOY) showed a 54% increase in the risk of COVID-19 lethality. LOY is associated with transcriptomic biomarkers of immune dysfunction, pro-coagulation activity and cardiovascular risk. Interferon-induced genes involved in the initial immune response to SARS-CoV-2 are also down-regulated in LOY. Thus, mCA and LOY underlie at least part of the sex-biased severity and mortality of COVID-19 in aging patients. Given its potential therapeutic and prognostic relevance, evaluation of clonal mosaicism should be implemented as biomarker of COVID-19 severity in elderly people. Among 9578 individuals diagnosed with COVID-19 in the SCOURGE study, individuals with clonal mosaic events (clonal mosaicism for chromosome alterations and/or loss of chromosome Y) showed an increased risk of COVID-19 lethality

A922 Sequential measurement of 1 hour creatinine clearance (1-CRCL) in critically ill patients at risk of acute kidney injury (AKI)

Meeting abstrac

Effect of liraglutide on physical performance in type 2 diabetes (LIPER2): A randomised, double-blind, controlled trial

Preclinical studies and small clinical trials suggest that glucagon-like peptide 1 (GLP1) may have a positive effect on ventricular function. Liraglutide is a GLP1-analogue used in the treatment of type 2 diabetes. LIPER2 is a phase IV, randomised, double-blind, placebo-controlled, parallel-design trial, assessing the effect of 6 months’ liraglutide 1.8 mg/d on measures of cardiac function and physical performance in patients with type 2 diabetes. A total of 30 patients with type 2 diabetes will be included, if their HbA1c is between 7 and 10% while on oral agents (including metformin if tolerated and not contraindicated), a maximum of 2 intermediate or long-acting insulin injections per day or a combination of both. After their baseline examinations, patients are randomised to receive a daily subcutaneous liraglutide or placebo injection (titrated to 1.8 mg/d if tolerated) for 6 months. The primary end-point is the maximal oxygen consumption during cycle ergometry at the end of the study period. Other end-points include distance covered during a 6-min walk test, left ventricular ejection fraction and other measures of ventricular systolic and diastolic functions assessed by echocardiography, heart rate, blood pressure, pro-brain natriuretic peptide, C-reactive protein, HbA1c, lipids, apolipoprotein B, body weight and waist girth. Safety end-points include adverse event reporting, blood count, kidney and liver function, amylase, lipase, electrolytes, calcitonin, CA19.9 and pregnancy test for fertile women. At the time of this report, recruitment is still ongoing. Results are expected to be reported in December 2016

GWAS and meta-analysis identifies 49 genetic variants underlying critical COVID-19

Data availability: Downloadable summary data are available through the GenOMICC data site (https://genomicc.org/data). Summary statistics are available, but without the 23andMe summary statistics, except for the 10,000 most significant hits, for which full summary statistics are available. The full GWAS summary statistics for the 23andMe discovery dataset will be made available through 23andMe to qualified researchers under an agreement with 23andMe that protects the privacy of the 23andMe participants. For further information and to apply for access to the data, see the 23andMe website (https://research.23andMe.com/dataset-access/). All individual-level genotype and whole-genome sequencing data (for both academic and commercial uses) can be accessed through the UKRI/HDR UK Outbreak Data Analysis Platform (https://odap.ac.uk). A restricted dataset for a subset of GenOMICC participants is also available through the Genomics England data service. Monocyte RNA-seq data are available under the title ‘Monocyte gene expression data’ within the Oxford University Research Archives (https://doi.org/10.5287/ora-ko7q2nq66). Sequencing data will be made freely available to organizations and researchers to conduct research in accordance with the UK Policy Framework for Health and Social Care Research through a data access agreement. Sequencing data have been deposited at the European Genome–Phenome Archive (EGA), which is hosted by the EBI and the CRG, under accession number EGAS00001007111.Extended data figures and tables are available online at https://www.nature.com/articles/s41586-023-06034-3#Sec21 .Supplementary information is available online at https://www.nature.com/articles/s41586-023-06034-3#Sec22 .Code availability: Code to calculate the imputation of P values on the basis of SNPs in linkage disequilibrium is available at GitHub (https://github.com/baillielab/GenOMICC_GWAS).Acknowledgements: We thank the members of the Banco Nacional de ADN and the GRA@CE cohort group; and the research participants and employees of 23andMe for making this work possible. A full list of contributors who have provided data that were collated in the HGI project, including previous iterations, is available online (https://www.covid19hg.org/acknowledgements).Change history: 11 July 2023: A Correction to this paper has been published at: https://doi.org/10.1038/s41586-023-06383-z. -- In the version of this article initially published, the name of Ana Margarita Baldión-Elorza, of the SCOURGE Consortium, appeared incorrectly (as Ana María Baldion) and has now been amended in the HTML and PDF versions of the article.Copyright © The Author(s) 2023, Critical illness in COVID-19 is an extreme and clinically homogeneous disease phenotype that we have previously shown1 to be highly efficient for discovery of genetic associations2. Despite the advanced stage of illness at presentation, we have shown that host genetics in patients who are critically ill with COVID-19 can identify immunomodulatory therapies with strong beneficial effects in this group3. Here we analyse 24,202 cases of COVID-19 with critical illness comprising a combination of microarray genotype and whole-genome sequencing data from cases of critical illness in the international GenOMICC (11,440 cases) study, combined with other studies recruiting hospitalized patients with a strong focus on severe and critical disease: ISARIC4C (676 cases) and the SCOURGE consortium (5,934 cases). To put these results in the context of existing work, we conduct a meta-analysis of the new GenOMICC genome-wide association study (GWAS) results with previously published data. We find 49 genome-wide significant associations, of which 16 have not been reported previously. To investigate the therapeutic implications of these findings, we infer the structural consequences of protein-coding variants, and combine our GWAS results with gene expression data using a monocyte transcriptome-wide association study (TWAS) model, as well as gene and protein expression using Mendelian randomization. We identify potentially druggable targets in multiple systems, including inflammatory signalling (JAK1), monocyte–macrophage activation and endothelial permeability (PDE4A), immunometabolism (SLC2A5 and AK5), and host factors required for viral entry and replication (TMPRSS2 and RAB2A).GenOMICC was funded by Sepsis Research (the Fiona Elizabeth Agnew Trust), the Intensive Care Society, a Wellcome Trust Senior Research Fellowship (to J.K.B., 223164/Z/21/Z), the Department of Health and Social Care (DHSC), Illumina, LifeArc, the Medical Research Council, UKRI, a BBSRC Institute Program Support Grant to the Roslin Institute (BBS/E/D/20002172, BBS/E/D/10002070 and BBS/E/D/30002275) and UKRI grants MC_PC_20004, MC_PC_19025, MC_PC_1905 and MRNO2995X/1. A.D.B. acknowledges funding from the Wellcome PhD training fellowship for clinicians (204979/Z/16/Z), the Edinburgh Clinical Academic Track (ECAT) programme. This research is supported in part by the Data and Connectivity National Core Study, led by Health Data Research UK in partnership with the Office for National Statistics and funded by UK Research and Innovation (grant MC_PC_20029). Laboratory work was funded by a Wellcome Intermediate Clinical Fellowship to B.F. (201488/Z/16/Z). We acknowledge the staff at NHS Digital, Public Health England and the Intensive Care National Audit and Research Centre who provided clinical data on the participants; and the National Institute for Healthcare Research Clinical Research Network (NIHR CRN) and the Chief Scientist’s Office (Scotland), who facilitate recruitment into research studies in NHS hospitals, and to the global ISARIC and InFACT consortia. GenOMICC genotype controls were obtained using UK Biobank Resource under project 788 funded by Roslin Institute Strategic Programme Grants from the BBSRC (BBS/E/D/10002070 and BBS/E/D/30002275) and Health Data Research UK (HDR-9004 and HDR-9003). UK Biobank data were used in the GSMR analyses presented here under project 66982. The UK Biobank was established by the Wellcome Trust medical charity, Medical Research Council, Department of Health, Scottish Government and the Northwest Regional Development Agency. It has also had funding from the Welsh Assembly Government, British Heart Foundation and Diabetes UK. The work of L.K. was supported by an RCUK Innovation Fellowship from the National Productivity Investment Fund (MR/R026408/1). J.Y. is supported by the Westlake Education Foundation. SCOURGE is funded by the Instituto de Salud Carlos III (COV20_00622 to A.C., PI20/00876 to C.F.), European Union (ERDF) ‘A way of making Europe’, Fundación Amancio Ortega, Banco de Santander (to A.C.), Cabildo Insular de Tenerife (CGIEU0000219140 ‘Apuestas científicas del ITER para colaborar en la lucha contra la COVID-19’ to C.F.) and Fundación Canaria Instituto de Investigación Sanitaria de Canarias (PIFIISC20/57 to C.F.). We also acknowledge the contribution of the Centro National de Genotipado (CEGEN) and Centro de Supercomputación de Galicia (CESGA) for funding this project by providing supercomputing infrastructures. A.D.L. is a recipient of fellowships from the National Council for Scientific and Technological Development (CNPq)-Brazil (309173/2019-1 and 201527/2020-0)